MichaelJBoeckhMD

Infectious Disease • Seattle, WA

Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Boeckh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boeckh's full profile

Already have an account?

Office
1100 Fairview Ave N
Seattle, WA 98109
Phone+1 206-667-4898

Fax+1 206-520-5620

Education & Training

University of WashingtonFellowship, Infectious Disease, 1990 - 1992
Freie University Berlin Faculty of MedicineClass of 1985

Certifications & Licensure

WA State Medical License 1993 - 2026

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Start of enrollment: 1999 Feb 01
Completed
Phase 3
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Start of enrollment: 2001 Jan 01
Completed
Phase 3
Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation Start of enrollment: 1998 Mar 01
Completed
Phase 3
Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant Start of enrollment: 1985 Jun 01
Completed
Phase 3
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study) Start of enrollment: 2008 Apr 01
Completed
Phase 3
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients Start of enrollment: 2009 Mar 01
Completed
Phase 1, Phase 2
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure Start of enrollment: 2011 Mar 10
Completed
Phase 2
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Completed
Phase 3
Dried Blood Spot Testing of CMV Detection in HCT Recipients Start of enrollment: 2019 May 03
Active, not recruiting
Not Applicable
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis Start of enrollment: 2021 Jun 29
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Correction: Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients.
Chikara Ogimi, Hu Xie, Alpana Waghmare, Keith R Jerome, Wendy M Leisenring
Bone Marrow Transplantation. 2024-12-01
1 citations
Understanding the Clinical Significance of Cytomegalovirus Viremia After Chimeric Antigen Receptor T-Cell Therapy: Should We be Treating a Value?
Eleftheria Kampouri, Michael J Boeckh, Joshua A Hill
Clinical Infectious Diseases. 2024-11-22
Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation.
Madeleine R Heldman, Michael J Boeckh, Ajit P Limaye
Clinical Infectious Diseases. 2024-11-04

Journal Articles

RNA Sequencing of the in Vivo Human Herpesvirus 6B Transcriptome to Identify Targets for Clinical Assays Distinguishing Between Latent and Active Infections
Joshua A Hill, Keith R Jerome, Michael Boeckh, mBio

Abstracts/Posters

Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Michael Boeckh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis
Michael Boeckh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Infectious Disease Scientists Look Beyond the PandemicMay 9th, 2023
AlloVir Reports Full-Year 2022 Financial Results and 2023 OutlookFebruary 17th, 2023
New Concerns About Coronavirus Evolution in Immunosuppressed PatientsAugust 4th, 2021
Join now to see all

Grant Support

A Randomzied Phase II Trial Of CMV Prevention In Acute Lung InjuryNational Heart, Lung, And Blood Institute2010–2011
Infections In Hematopoietic Cell Transplant RecipientsNational Heart, Lung, And Blood Institute2009–2011
Microbiology And Virology CoreNational Cancer Institute2007–2011
Respiratory Viruses And Airflow Obstruction After HCTNational Heart, Lung, And Blood Institute2005–2008
Core--Microbiology And VirologyNational Cancer Institute2002
CMV And HIV SheddingEunice Kennedy Shriver National Institute Of Child Health &Human Development2002